Targeted therapies for lung cancer patients with oncogenic driver molecular alterations
Lung cancer has traditionally been classified by histology. However, a greater
understanding of disease biology and the identification of oncogenic driver alterations has …
understanding of disease biology and the identification of oncogenic driver alterations has …
Clinical trial design in the era of precision medicine
E Fountzilas, AM Tsimberidou, HH Vo, R Kurzrock - Genome medicine, 2022 - Springer
Recent rapid biotechnological breakthroughs have led to the identification of complex and
unique molecular features that drive malignancies. Precision medicine has exploited next …
unique molecular features that drive malignancies. Precision medicine has exploited next …
Non–small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell
Lung Cancer (NSCLC) provide recommended management for patients with NSCLC …
Lung Cancer (NSCLC) provide recommended management for patients with NSCLC …
EGFR signaling pathway as therapeutic target in human cancers
Abstract Epidermal Growth Factor Receptor (EGFR) enacts major roles in the maintenance
of epithelial tissues. However, when EGFR signaling is altered, it becomes the grand …
of epithelial tissues. However, when EGFR signaling is altered, it becomes the grand …
The biology and management of non-small cell lung cancer
RS Herbst, D Morgensztern, C Boshoff - Nature, 2018 - nature.com
Important advancements in the treatment of non-small cell lung cancer (NSCLC) have been
achieved over the past two decades, increasing our understanding of the disease biology …
achieved over the past two decades, increasing our understanding of the disease biology …
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label …
YL Wu, Y Cheng, X Zhou, KH Lee, K Nakagawa… - The Lancet …, 2017 - thelancet.com
Background Dacomitinib is a second-generation, irreversible EGFR tyrosine kinase inhibitor.
We compared its efficacy and safety with that of the reversible EGFR tyrosine kinase inhibitor …
We compared its efficacy and safety with that of the reversible EGFR tyrosine kinase inhibitor …
Non–small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology
This selection from the NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC)
focuses on targeted therapies and immunotherapies for metastatic NSCLC, because …
focuses on targeted therapies and immunotherapies for metastatic NSCLC, because …
Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer
PURPOSE Standard first-line therapy for EGFR-mutant advanced non–small-cell lung
cancer (NSCLC) is an epidermal growth factor receptor (EGFR)–directed oral tyrosine …
cancer (NSCLC) is an epidermal growth factor receptor (EGFR)–directed oral tyrosine …
[HTML][HTML] Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
L Paz-Ares, EH Tan, K O'Byrne, L Zhang, V Hirsh… - Annals of …, 2017 - Elsevier
ABSTRACT Background In LUX-Lung 7, the irreversible ErbB family blocker, afatinib,
significantly improved progression-free survival (PFS), time-to-treatment failure (TTF) and …
significantly improved progression-free survival (PFS), time-to-treatment failure (TTF) and …
Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
The traditional approach to the treatment of patients with advanced-stage non-small-cell
lung carcinoma (NSCLC) harbouring ALK rearrangements or EGFR mutations has been the …
lung carcinoma (NSCLC) harbouring ALK rearrangements or EGFR mutations has been the …